2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 339

Differences Between Juvenile and Adult Rodents with Collagen Induced Arthritis
Abstract Number: 1085

Differences in Baseline Characteristics Between TKR and THR Patients: Results From a National Research Consortium
Abstract Number: 521

Differences in Genome-Wide DNA Methylation Profiles Across Multiple Cell and Tissue Types in Sjögren’s Syndrome (SS)
Abstract Number: 2058

Differences in Psychological Characteristics Between Patients with Rheumatoid and Psoriatic Arthritis
Abstract Number: 369

Differences in Short-Term Radiographic Progression Following Early Response to Adalimumab Plus Methotrexate Vs. Methotrexate Alone
Abstract Number: 1514

Differences in the Activation Levels and Expression Patterns of the Molecular Targets of Tyrosine Kinase Inhibitors May Account for the Heterogeneous Treatment Responses
Abstract Number: 550

Differences in the Prevalence of Inflammatory Articular Disease in Psoriatic Patients, Applying Clinical, Ultrasound and/or Radiological Data. Implications in the Classification of Psoriatic Arthritis according to Caspar Criteria
Abstract Number: 671

Differences in the SLE Clinical Phenotype by Age of Diagnosis
Abstract Number: 1791

Different Mechanisms Responsible for IVIG Inhibition of Immune Complex Versus TLR Stimulated Interferon-Alpha
Abstract Number: 1128

Different of Patterns Knee Pain Trajectories: Longitudinal Data From the Osteoarthritis Initiative (OAI)
Abstract Number: 573

Differential Association Between Human Leukocyte Antigen (HLA) Alleles and Joint Subluxation and Ankylosis in Patients with Psoriatic Arthritis
Abstract Number: 2304

Differential Association of IRAK1 and MECP2 with Specific Systemic Sclerosis Phenotypes
Abstract Number: 1329

Differential Effect of 4 and 8 Mg/Kg Tocilizumab in Combination with Methotrexate On Serum Biomarkers of Cartilage, Connective Tissue and Bone Turnover
Abstract Number: 23

Differential Effects of Bone Morphogenetic Protein 2 and 9 On Chondroprotective Transforming Growth Factor β Signaling
Abstract Number: 1471

Differential Expression of Hepatocyte Growth Factor (HGF) in Patients with Systemic Sclerosis-Associated Pulmonary Arterial Hypertension

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].